Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.
Why it matters: Paxlovid’s new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.
Maybe. Definite grounds for violation of price gouging laws unless another producer can easily fill the supply gap, which is entirely reliant on how much time is left before the change AND the availability of production methods which are beholden to intellectual property laws.